VEGFA and metabolic syndrome: It suggests that some patients with dyslipidemia may exhibit heightened responsiveness to anti-VEGF treatment, potentially due to inflammatory and vascular mechanisms associated with lipid metabolism [13,14], opening the door for more personalized therapeutic strategies (Figure 7).